Clinical Trial Update: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab, ipilimumab, and bicalutamide for HER2-negative breast cancer is active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Casodex (bicalutamide) (bicalutamide)
• Opdivo (nivolumab) (nivolumab)
• Yervoy (Ipilimumab) (Ipilimumab)

Snippet

Sponsor: Providence Health & Services | Conditions: Breast Neoplasm Female, Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING